Signal transduction by tumor necrosis factor and gene regulation of the inflammatory cytokine interleukin-6

Biochemical Pharmacology

Volumn 60, Issue 8, 2000, Pages 1185-1195

  Vanden Berghe, Wim ^a   Vermeulen, Linda ^a   De Wilde, Gert ^a   De Bosscher, Karolien ^a   Boone, Elke ^a   Haegeman, Guy ^a  

^a DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

Author keywords

Acetyltransferase; Coactivator; Corepressor; Deacetylase; Glucocorticoid; Interleukin 6; NF B; Tumor necrosis factor

Indexed keywords

CYTOKINE; GLUCOCORTICOID RECEPTOR; HISTONE; HISTONE ACETYLTRANSFERASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN P55; PROTEIN SUBUNIT; TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR;

ACETYLATION; CELL ACTIVATION; GENE ACTIVATION; GENE CONTROL; GENE EXPRESSION; GENE INDUCTION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION;

ANIMAL; ENHANCER ELEMENTS (GENETICS); GENE EXPRESSION REGULATION; HUMAN; INTERLEUKIN-6; NF-KAPPA B; RECEPTORS, TUMOR NECROSIS FACTOR; SIGNAL TRANSDUCTION; SUPPORT, NON-U.S. GOV'T; TUMOR NECROSIS FACTOR;

EID: 0034668173     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(00)00412-3     Document Type: Article

References (201)

1. Koj A. Initiation of acute phase response and synthesis of cytokines. Biochim Biophys Acta. 1317:1996;84-94.
2. Feghali C., Wright T. Cytokines in acute and chronic inflammation. Front Biosci. 2:1997;d12-d26.
3. Verhasselt V., Vanden Berghe W., Vanderheyde N., Willems F., Haegeman G., Goldman M. N-acetyl-L-cysteine inhibits primary human T cell responses at the dendritic cell level Association with NF-κB inhibition. J Immunol. 162:1999;2569-2574.
4. Akira S., Taga T., Kishimoto T. Interleukin-6 in biology and medicine. Adv Immunol. 54:1993;1-78.
5. Gadient R.A., Otten U.H. Interleukin-6 (IL-6) - A molecule with both beneficial and destructive potentials. Prog Neurobiol. 52:1997;379-390.
6. Papanicolaou D.A., Wilder R.L., Manolagas S.C., Chrousos G.P. The pathophysiologic roles of interleukin-6 in human disease. Ann Intern Med. 128:1998;127-137.
7. Erschler W.B., Keller E.T. Age-associated increased interleukin-6 gene expression, late-life diseases, and frailty. Annu Rev Med. 51:2000;245-270.
8. Wang L.S., Chow K.C., Wu C.W. Expression and up-regulation of interleukin-6 in oesophageal carcinoma cells by n-sodium butyrate. Br J Cancer. 80:1999;1617-1622.
9. Zhang G.J., Adachi I. Serum interleukin-6 levels correlate to tumor progression and prognosis in metastatic breast carcinoma. Anticancer Res. 19:1999;1427-1432.
10. Young P.R. Pharmacological modulation of cytokine action and production through signaling pathways. Cytokine Growth Factor Rev. 9:1998;239-257.
11. Bhagwat S.S., Manning A.M., Hoekstra M.F., Lewis A. Gene-regulating protein kinases as important anti-inflammatory targets. Drug Discov Today. 4:1999;472-479.
12. Cohen P. The development and therapeutic potential of protein kinase inhibitors. Curr Opin Chem Biol. 3:1999;459-465.
13. Han J., Ulevitch R.J. Emerging targets for anti-inflammatory therapy. Nat Cell Biol. 1:1999;E39-E40.
14. Herlaar E., Brown Z. p38 MAPK signalling cascades in inflammatory disease. Mol Med Today. 5:1999;439-447.
15. Lewis A.J., Manning A.M. New targets for anti-inflammatory drugs. Curr Opin Chem Biol. 3:1999;489-494.
16. Patestos N.P., Haegeman G., Vandevoorde V., Fiers W. Activation of the nuclear factor κB is not sufficient for regulation of tumor necrosis factor-induced interleukin-6 gene expression. Biochimie. 75:1993;1007-1018.
17. Dendorfer U., Oettgen P., Libermann T.A. Multiple regulatory elements in the interleukin-6 gene mediate induction by prostaglandins, cyclic AMP, and lipopolysaccharide. Mol Cell Biol. 14:1994;4443-4454.
18. Vanhoenacker P., Fiers W., Haegeman G. Studies on the induction of the interleukin-6 promoter in cell lines of human and simian origin. Eur Cytokine Netw. 5:1994;283-291.
19. Sanceau J., Kaisho T., Hirano T., Wietzerbin J. Triggering of the human interleukin-6 gene by interferon-γ and tumor necrosis factor-α in monocytic cells involves cooperation between interferon regulatory factor-1, NF-κB, and Sp1 transcription factors. J Biol Chem. 270:1995;27920-27931.
20. Haegeman G and Fiers W, TNF-induced mechanisms for IL6 gene induction. In: Signalling Mechanisms - From Transcription Factors to Oxidative Stress, NATO ASI Series (Eds. Packer L and Wirtz K), Vol. H 92, pp. 375-382. Springer, Berlin/Heidelberg/New York, 1995.
21. Ambrosino C., Ruocco M.R., Chen X., Mallardo M., Baudi F., Trematerra S., Quinto I., Venuta S., Scala G. HIV-1 Tat induces the expression of the interleukin-6 (IL6) gene by binding to the IL6 leader RNA and by interacting with CAAT enhancer-binding protein β (NF-IL6) transcription factors. J Biol Chem. 272:1997;14883-14892.
22. Vanden Berghe W., Plaisance S., Boone E., De Bosscher K., Schmitz M.L., Fiers W., Haegeman G. p38 and extracellular signal-regulated kinase mitogen-activated protein kinase pathways are required for nuclear factor-κB p65 transactivation mediated by tumor necrosis factor. J Biol Chem. 273:1998;3285-3290.
23. Vanden Berghe W., De Bosscher K., Boone E., Plaisance S., Haegeman G. The nuclear factor-κB engages CBP/p300 and histone acetyltransferase activity for transcriptional activation of the interleukin-6 gene promoter. J Biol Chem. 274:1999;32091-32098.
24. Fiers W., Beyaert R., Boone E., Cornelis S., Declercq W., Decoster E., Denecker G., Depuydt B., De Valck D., De Wilde G., Goossens V., Grooten J., Haegeman G., Heyninck K., Penning L., Plaisance S., Vancompernolle K., Van Criekinge W., Vandenabeele P., Vanden Berghe W., Van de Craen M., Vandevoorde V., Vercammen D. TNF-induced intracellular signaling leading to gene induction or to cytotoxicity by necrosis or by apoptosis. J Inflamm. 47:1995;67-75.
25. Vandenabeele P., Declercq W., Beyaert R., Fiers W. Two tumour necrosis factor receptors Structure and function. Trends Cell Biol. 5:1995;392-399.
26. Wallach D., Varfolomeev E.E., Malinin N.L., Goltsev Y.V., Kovalenko A.V., Boldin M.P. Tumor necrosis factor receptor and Fas signaling mechanisms. Annu Rev Immunol. 17:1999;331-367.
27. Heyninck K., De Valck D., Vanden Berghe W., Van Criekinge W., Contreras R., Fiers W., Haegeman G., Beyaert R. The zinc finger protein A20 inhibits TNF-induced NF-κB-dependent gene expression by interfering with an RIP- or TRAF2-mediated transactivation signal and directly binds to a novel NF-κB-inhibiting protein ABIN. J Cell Biol. 145:1999;1471-1482.
28. Zhang S.Q., Kovalenko A., Cantarella G., Wallach D. Recruitment of the IKK signalosome to the p55 TNF receptor RIP and A20 bind to NEMO (IKKγ) upon receptor stimulation. Immunity. 12:2000;301-311.
29. Vandevoorde V., Haegeman G., Fiers W. Induced expression of trimerized intracellular domains of the human tumor necrosis factor (TNF) p55 receptor elicits TNF effects. J Cell Biol. 137:1997;1627-1638.
30. Boone E., Vandevoorde V., De Wilde G., Haegeman G. Activation of p42/p44 mitogen-activated protein kinases (MAPK) and p38 MAPK by tumor necrosis factor (TNF) is mediated through the death domain of the 55-kDa TNF receptor. FEBS Lett. 441:1998;275-280.
31. Baeuerle P.A., Baltimore D. IκB a specific inhibitor of the NF-κB transcription factor. Science. 242:1988;540-546.
32. Pahl H.L. Activators and target genes of Rel/NF-κB transcription factors. Oncogene. 18:1999;6853-6866.
33. Epinat J.C., Gilmore T.D. Diverse agents act at multiple levels to inhibit the Rel/NF-κB signal transduction pathway. Oncogene. 18:1999;6896-6909.
34. Grilli M., Memo M. Nuclear factor-κB/Rel proteins A point of convergence of signalling pathways relevant in neuronal function and dysfunction. Biochem Pharmacol. 57:1999;1-7.
35. Karin M. How NF-κB is activated The role of the IκB kinase (IKK) complex. Oncogene. 18:1999;6867-6874.
36. Mercurio F., Manning A.M. Multiple signals converging on NF-κB. Curr Opin Cell Biol. 11:1999;226-232.
37. Rothwarf DM and Karin M, The NF-κB activation pathway: A paradigm in information transfer from membrane to nucleus. Science’s STKE, www.stke.org/cgi/content/full/OC_sigtrans 5: 1-16, 1999.
38. Hatada E.N., Krappmann D., Scheidereit C. NF-κB and the innate immune response. Curr Opin Immunol. 12:2000;52-58.
39. Israël A. The IKK complex An integrator of all signals that activate NF-κB. Trends Cell Biol. 10:2000;129-133.
40. Imbert V., Rupec R.A., Livolsi A., Pahl H.L., Traenckner E.B., Mueller-Dieckmann C., Farahifar D., Rossi B., Auberger P., Baeuerle P.A., Peyron J.F. Tyrosine phosphorylation of IκB-α activates NF-κB without proteolytic degradation of IκB-α Cell. 86:1996;787-798.
41. Bender K., Gottlicher M., Whiteside S., Rahmsdorf H.J., Herrlich P. Sequential DNA damage-independent and -dependent activation of NF-κB by UV. EMBO J. 17:1998;5170-5181.
42. Li N., Karin M. Ionizing radiation and short wavelength UV activate NF-κB through two distinct mechanisms. Proc Natl Acad Sci USA. 95:1998;13012-13017.
43. Belich M.P., Salmeron A., Johnston L.H., Ley S.C. TPL-2 kinase regulates the proteolysis of the NF-κB-inhibitory protein NF-κB1 p105. Nature. 397:1999;363-368.
44. Bonizzi G., Piette J., Schoonbroodt S., Greimers R., Havard L., Merville M.P., Bours V. Reactive oxygen intermediate-dependent NF-κB activation by interleukin-1-β requires 5-lipoxygenase or NADPH oxidase activity. Mol Cell Biol. 19:1999;1950-1960.
45. Pomerantz J.L., Baltimore D. NF-κB activation by a signaling complex containing TRAF2, TANK and TBK1, a novel IKK-related kinase. EMBO J. 18:1999;6694-6704.
46. Peters R.T., Liao S.M., Maniatis T. IKKε is part of a novel PMA-inducible IκB kinase complex. Mol Cell. 5:2000;513.
47. Beyaert R., Cuenda A., Vanden Berghe W., Plaisance S., Lee J.C., Haegeman G., Cohen P., Fiers W. The p38/RK mitogen-activated protein kinase pathway regulates interleukin-6 synthesis in response to tumour necrosis factor. EMBO J. 15:1996;1914-1923.
48. Naumann M., Scheidereit C. Activation of NF-κB in vivo is regulated by multiple phosphorylations. EMBO J. 13:1994;4597-4607.
49. Li C.C., Korner M., Ferris D.K., Chen E., Dai R.M., Longo D.L. NF-κB/Rel family members are physically associated phosphoproteins. Biochem J. 303:1994;499-506.
50. Diehl J.A., Tong W., Sun G., Hannink M. Tumor necrosis factor-α-dependent activation of a RelA homodimer in astrocytes. Increased phosphorylation of RelA and MAD-3 precede activation of RelA. J Biol Chem. 270:1995;2703-2707.
51. Bird T.A., Schooley K., Dower S.K., Hagen H., Virca G.D. Activation of nuclear transcription factor NF-κB by interleukin-1 is accompanied by casein kinase II-mediated phosphorylation of the p65 subunit. J Biol Chem. 272:1997;32606-32612.
52. Wang D., Baldwin A.S. Activation of nuclear factor-κB-dependent transcription by tumor necrosis factor-α is mediated through phosphorylation of RelA/p65 on serine 529. J Biol Chem. 273:1998;29411-29416.
53. Zhong H., Voll R.E., Ghosh S. Phosphorylation of NF-κB p65 by PKA stimulates transcriptional activity by promoting a novel bivalent interaction with the coactivator CBP/p300. Mol Cell. 1:1998;661-671.
54. Anrather J., Csizmadia V., Soares M.P., Winkler H. Regulation of NF-κB RelA phosphorylation and transcriptional activity by p21(ras) and protein kinase C-ζ in primary endothelial cells. J Biol Chem. 274:1999;13594-13603.
55. Egan L.J., Mays D.C., Huntoon C.J., Bell M.P., Pike M.G., Sandborn W.J., Lipsky J.J., McKean D.J. Inhibition of interleukin-1-stimulated NF-κB RelA/p65 phosphorylation by mesalamine is accompanied by decreased transcriptional activity. J Biol Chem. 274:1999;26448-26453.
56. Sakurai H., Chiba H., Miyoshi H., Sugita T., Toriumi W. IκB kinases phosphorylate NF-κB p65 subunit on serine 536 in the transactivation domain. J Biol Chem. 274:1999;30353-30356.
57. Shumilla J.A., Broderick R.J., Wang Y., Barchowsky A. Chromium(VI) inhibits the transcriptional activity of nuclear factor-κB by decreasing the interaction of p65 with cAMP-responsive element-binding protein-binding protein. J Biol Chem. 274:1999;36207-36212.
58. Sizemore N., Leung S., Stark G.R. Activation of phosphatidylinositol 3-kinase in response to interleukin-1 leads to phosphorylation and activation of the NF-κB p65/RelA subunit. Mol Cell Biol. 19:1999;4798-4805.
59. Madrid L.V., Wang C.Y., Guttridge D.C., Schottelius A.J., Baldwin A.S., Mayo M.W. Akt suppresses apoptosis by stimulating the transactivation potential of the RelA/p65 subunit of NF-κB. Mol Cell Biol. 20:2000;1626-1638.
60. Drier E.A., Huang L.H., Steward R. Nuclear import of the Drosophila Rel protein Dorsal is regulated by phosphorylation. Genes Dev. 13:1999;556-568.
61. Huxford T., Huang D.B., Malek S., Ghosh G. The crystal structure of the IκB-α/NF-κB complex reveals mechanisms of NF-κB inactivation. Cell. 95:1998;759-770.
62. Jacobs M.D., Harrison S.C. Structure of an IκB-α/NF-κB complex. Cell. 95:1998;749-758.
63. Chen F.E., Huang D.B., Chen Y.Q., Ghosh G. Crystal structure of p50/p65 heterodimer of transcription factor NF-κB bound to DNA. Nature. 391:1998;410-413.
64. Cramer P., Muller C.W. A firm hand on NF-κB Structures of the IκB-α-NF-κB complex. Structure Fold Des. 7:1999;R1-R6.
65. Torchia J., Glass C., Rosenfeld M.G. Co-activators and co-repressors in the integration of transcriptional responses. Curr Opin Cell Biol. 10:1998;373-383.
66. Kuo M.H., Allis C.D. Roles of histone acetyltransferases and deacetylases in gene regulation. Bioessays. 20:1998;615-626.
67. Berger S.L. Gene activation by histone and factor acetyltransferases. Curr Opin Cell Biol. 11:1999;336-341.
68. Sheppard K.A., Rose D.W., Haque Z.K., Kurokawa R., McInerney E., Westin S., Thanos D., Rosenfeld M.G., Glass C.K., Collins T. Transcriptional activation by NF-κB requires multiple coactivators. Mol Cell Biol. 19:1999;6367-6378.
69. Gregory P.D., Horz W. Chromatin and transcription - how transcription factors battle with a repressive chromatin environment. Eur J Biochem. 251:1998;9-18.
70. Kadonaga J.T. Eukaryotic transcription An interlaced network of transcription factors and chromatin-modifying machines. Cell. 92:1998;307-313.
71. Wolffe A.P., Hayes J.J. Chromatin disruption and modification. Nucleic Acids Res. 27:1999;711-720.
72. Strahl B.D., Allis C.D. The language of covalent histone modifications. Nature. 403:2000;41-45.
73. Merika M., Williams A.J., Chen G., Collins T., Thanos D. Recruitment of CBP/p300 by the IFNβ enhanceosome is required for synergistic activation of transcription. Mol Cell. 1:1998;277-287.
74. Snowden A.W., Perkins N.D. Cell cycle regulation of the transcriptional coactivators p300 and CREB binding protein. Biochem Pharmacol. 55:1998;1947-1954.
75. Chen D., Ma H., Hong H., Koh S.S., Huang S.M., Schurter B.T., Aswad D.W., Stallcup M.R. Regulation of transcription by a protein methyltransferase. Science. 284:1999;2174-2177.
76. Hagmann M. How chromatin changes its shape. Science. 285:1999;1200-1201.
77. Jin Y., Wang Y., Walker D.L., Dong H., Conley C., Johansen J., Johansen K.M. JIL-1 A novel chromosomal tandem kinase implicated in transcriptional regulation in Drosophila. Mol Cell. 4:1999;129-135.
78. Parekh B.S., Maniatis T. Virus infection leads to localized hyperacetylation of histones H3 and H4 at the IFNβ promoter. Mol Cell. 3:1999;125-129.
79. Michael L.F., Asahara H., Shulman A.I., Kraus W.L., Montminy M. The phosphorylation status of a cyclic AMP-responsive activator is modulated via a chromatin-dependent mechanism. Mol Cell Biol. 20:2000;1596-1603.
80. Robzyk K., Recht J., Osley M.A. Rad6-dependent ubiquitination of histone H2B in yeast. Science. 287:2000;501-504.
81. Pollard K.J., Peterson C.L. Chromatin remodeling A marriage between two families? Bioessays. 20:1998;771-780.
82. Hampsey M., Reinberg D. RNA polymerase II as a control panel for multiple coactivator complexes. Curr Opin Genet Dev. 9:1999;132-139.
83. Kornberg R.D., Lorch Y. Chromatin-modifying and -remodeling complexes. Curr Opin Genet Dev. 9:1999;148-151.
84. Muraoka M., Konishi M., Kikuchi Yanoshita R., Tanaka K., Shitara N., Chong J.M., Iwama T., Miyaki M. p300 gene alterations in colorectal and gastric carcinomas. Oncogene. 12:1996;1565-1569.
85. Giles R.H., Peters D.J., Breuning M.H. Conjunction dysfunction CBP/p300 in human disease. Trends Genet. 14:1998;178-183.
86. Archer S.Y., Hodin R.A. Histone acetylation and cancer. Curr Opin Genet Dev. 9:1999;171-174.
87. Jacobson S., Pillus L. Modifying chromatin and concepts of cancer. Curr Opin Genet Dev. 9:1999;175-184.
88. Kouzarides T. Histone acetylases and deacetylases in cell proliferation. Curr Opin Genet Dev. 9:1999;40-48.
89. Blobel G.A. CREB-binding protein and p300 Molecular integrators of hematopoietic transcription. Blood. 95:2000;745-755.
90. Kung A.L., Rebel V.I., Bronson R.T., Ch’ng L.E., Sieff C.A., Livingston D.M., Yao T.P. Gene dose-dependent control of hematopoiesis and hematologic tumor suppression by CBP. Genes Dev. 14:2000;272-277.
91. Schiltz R.L., Nakatani Y. The PCAF acetylase complex as a potential tumor suppressor. Biochim Biophys Acta. 1470:2000;M37-M53.
92. Xu L., Lavinsky R.M., Dasen J.S., Flynn S.E., McInerney E.M., Mullen T.M., Heinzel T., Szeto D., Korzus E., Kurokawa R., Aggarwal A.K., Rose D.W., Glass C.K., Rosenfeld M.G. Signal-specific co-activator domain requirements for Pit-1 activation. Nature. 395:1998;301-306.
93. Hong S.H., Wong C.W., Privalsky M.L. Signaling by tyrosine kinases negatively regulates the interaction between transcription factors and SMRT (silencing mediator of retinoic acid and thyroid hormone receptor) corepressor. Mol Endocrinol. 12:1998;1161-1171.
94. Kawasaki H., Eckner R., Yao T.P., Taira K., Chiu R., Livingston D.M., Yokoyama K.K. Distinct roles of the co-activators p300 and CBP in retinoic-acid-induced F9-cell differentiation. Nature. 393:1998;284-289.
95. Korzus E., Torchia J., Rose D.W., Xu L., Kurokawa R., McInerney E.M., Mullen T.M., Glass C.K., Rosenfeld M.G. Transcription factor-specific requirements for coactivators and their acetyltransferase functions. Science. 279:1998;703-707.
96. Utley R.T., Ikeda K., Grant P.A., Cote J., Steger D.J., Eberharter A., John S., Workman J.L. Transcriptional activators direct histone acetyltransferase complexes to nucleosomes. Nature. 394:1998;498-502.
97. Ikeda K., Steger D.J., Eberharter A., Workman J.L. Activation domain-specific and general transcription stimulation by native histone acetyltransferase complexes. Mol Cell Biol. 19:1999;855-863.
98. Perissi V., Dasen J.S., Kurokawa R., Wang Z.Y., Korzus E., Rose D.W., Glass C.K., Rosenfeld M.G. Factor-specific modulation of CREB-binding protein acetyltransferase activity. Proc Natl Acad Sci USA. 96:1999;3652-3657.
99. Van Lint C., Emiliani S., Ott M., Verdin E. Transcriptional activation and chromatin remodeling of the HIV-1 promoter in response to histone acetylation. EMBO J. 15:1996;1112-1120.
100. Sheridan P.L., Mayall T.P., Verdin E., Jones K.A. Histone acetyltransferases regulate HIV-1 enhancer activity in vitro. Genes Dev. 11:1997;3327-3340.
101. El Kharroubi A., Piras G., Zensen R., Martin M.A. Transcriptional activation of the integrated chromatin-associated human immunodeficiency virus type 1 promoter. Mol Cell Biol. 18:1998;2535-2544.
102. Parker D., Jhala U.S., Radhakrishnan I., Yaffe M.B., Reyes C., Shulman A.I., Cantley L.C., Wright P.E., Montminy M. Analysis of an activator:coactivator complex reveals an essential role for secondary structure in transcriptional activation. Mol Cell. 2:1998;353-359.
103. Radhakrishnan I., Perez-Alvarado G.C., Parker D., Dyson H.J., Montminy M.R., Wright P.E. Solution structure of the KIX domain of CBP bound to the transactivation domain of CREB. A model for activator:coactivator interactions. Cell. 91:1998;741-752.
104. Akimaru H., Hou-Dx, Ishii S. Drosophila CBP is required for dorsal-dependent twist gene expression. Nat Genet. 17:1997;211-214.
105. Gerritsen M.E., Williams A.J., Neish A.S., Moore S., Shi Y., Collins T. CREB-binding protein/p300 are transcriptional coactivators of p65. Proc Natl Acad Sci USA. 94:1997;2927-2932.
106. Perkins N.D., Felzien L.K., Betts J.C., Leung K., Beach D.H., Nabel G.J. Regulation of NF-κB by cyclin-dependent kinases associated with the p300 coactivator. Science. 275:1997;523-527.
107. Merika M., Williams A.J., Chen G., Collins T., Thanos D. Recruitment of CBP/p300 by the IFNβ enhanceosome is required for synergistic activation of transcription. Mol Cell. 1:1998;277-287.
108. Torchia J., Rose D.W., Inostroza J., Kamei Y., Westin S., Glass C.K., Rosenfeld M.G. The transcriptional co-activator p/CIP binds CBP and mediates nuclear-receptor function. Nature. 387:1997;677-684.
109. Min W., Ghosh S., Lengyel P. The interferon-inducible p202 protein as a modulator of transcription Inhibition of NF-κB, c-Fos, and c-Jun activities. Mol Cell Biol. 16:1996;359-368.
110. Dubnicoff T., Valentine S.A., Chen G., Shi T., Lengyel J.A., Paroush Z., Courey A.J. Conversion of dorsal from an activator to a repressor by the global corepressor Groucho. Genes Dev. 11:1997;2952-2957.
111. Na S.Y., Lee S.K., Han S.J., Choi H.S., Im S.Y., Lee J.W. Steroid receptor coactivator-1 interacts with the p50 subunit and coactivates nuclear factor κB-mediated transactivations. J Biol Chem. 273:1998;10831-10834.
112. Valentine S.A., Chen G., Shandala T., Fernandez J., Mische S., Saint R., Courey A.J. Dorsal-mediated repression requires the formation of a multiprotein repression complex at the ventral silencer. Mol Cell Biol. 18:1998;6584-6594.
113. Dechend R., Hirano F., Lehmann K., Heissmeyer V., Ansieau S., Wulczyn F.G., Scheidereit C., Leutz A. The Bcl-3 oncoprotein acts as a bridging factor between NF-κB/Rel and nuclear co-regulators. Oncogene. 18:1999;3316-3323.
114. Heissmeyer V., Krappmann D., Wulczyn F.G., Scheidereit C. NF-κB p105 is a target of IκB kinases and controls signal induction of Bcl-3-p50 complexes. EMBO J. 18:1999;4766-4778.
115. Naar A.M., Beaurang P.A., Zhou S., Abraham S., Solomon W., Tjian R. Composite co-activator ARC mediates chromatin-directed transcriptional activation. Nature. 398:1999;828-832.
116. Tetsuka T., Uranishi H., Imai H., Ono T., Sonta S., Takahashi N., Asamitsu K., Okamoto T. Inhibition of nuclear factor-κB-mediated transcription by association with the amino-terminal enhancer of split, a groucho-related protein lacking WD40 repeats. J Biol Chem. 275:2000;4383-4390.
117. Wen Y., Yan D.H., Spohn B., Deng J., Lin S.Y., Hung M.C. Tumor suppression and sensitization to tumor necrosis factor α-induced apoptosis by an interferon-inducible protein, p202, in breast cancer cells. Cancer Res. 60:2000;42-46.
118. Glass C.K., Rosenfeld M.G. The coregulator exchange in transcriptional functions of nuclear receptors. Genes Dev. 14:2000;121-141.
119. Sakaguchi K., Herrera J.E., Saito S., Miki T., Bustin M., Vassilev A., Anderson C.W., Appella E. DNA damage activates p53 through a phosphorylation-acetylation cascade. Genes Dev. 12:1998;2831-2841.
120. Kouzarides T. Acetylation A regulatory modification to rival phosphorylation? EMBO J. 19:2000;1176-1179.
121. Munshi N., Merika M., Yie J., Senger K., Chen G., Thanos D. Acetylation of HMG I(Y) by CBP turns off IFNβ expression by disrupting the enhanceosome. Mol Cell. 2:1998;457-468.
122. Gu W., Roeder R.G. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell. 90:1997;595-606.
123. Medina V., Edmonds B., Young G.P., James R., Appleton S., Zalewski P.D. Induction of caspase-3 protease activity and apoptosis by butyrate and trichostatin A (inhibitors of histone deacetylase) Dependence on protein synthesis and synergy with a mitochrondrial cytochrome c-dependent pathway. Cancer Res. 57:1997;3697-3707.
124. Bestor T.H. Methylation meets acetylation. Nature. 393:1998;311-389.
125. Jones P.L., Veenstra G.J., Wade P.A., Vermaak D., Kass S.U., Landsberger N., Strouboulis J., Wolffe A.P. Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat Genet. 19:1998;187-191.
126. Nan X., Ng H.H., Johnson C.A., Laherty C.D., Turner B.M., Eisenman R.N., Bird A. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature. 393:1998;386-389.
127. Fuks F., Burgers W.A., Brehm A., Hughes-Davies L., Kouzarides T. DNA methyltransferase Dnmt1 associates with histone deacetylase activity. Nat Genet. 24:2000;88-91.
128. Alberts A.S., Geneste O., Treisman R. Activation of SRF-regulated chromosomal templates by rho-family GTPases requires a signal that also induces H4 hyperacetylation. Cell. 92:1998;475-487.
129. Espinos E., Le Van Thai A., Pomies C., Weber M.J. Cooperation between phosphorylation and acetylation processes in transcriptional control. Mol Cell Biol. 19:1999;3474-3484.
130. Witt O., Sand K., Pekrun A. Butyrate-induced erythroid differentiation of human K562 leukemia cells involves inhibition of ERK and activation of p38 MAP kinase pathways. Blood. 95:2000;2391-2396.
131. Carter A.B., Knudtson K.L., Monick M.M., Hunninghake G.W. The p38 mitogen-activated protein kinase is required for NF-κB-dependent gene expression. The role of TATA-binding protein (TBP). J Biol Chem. 274:1999;30858-30863.
132. Nakajima T., Fukimizu A., Takahashi J., Gage F.H., Fisher T., Blenis J., Montminy M.R. The signal-dependent coactivator CBP is a nuclear target for pp90rsk. Cell. 86:1996;465-474.
133. Ait-Si-Ali S., Ramirez S., Barre F.X., Dkhissi F., Magnaghi-Jaulin L., Girault J.A., Robin P., Knibiehler M., Pritchard L.L., Ducommun B., Trouche D., Harel-Bellan A. Histone acetyltransferase activity of CBP is controlled by cycle-dependent kinases and oncoprotein E1A. Nature. 396:1998;184-186.
134. Chawla S., Hardingham G.E., Quinn D.R., Bading H. CBP A signal-regulated transcriptional coactivator controlled by nuclear calcium and CaM kinase IV. Science. 281:1998;1505-1509.
135. Liu Y.Z., Chrivia J.C., Latchman D.S. Nerve growth factor up-regulates the transcriptional activity of CBP through activation of the p42/p44(MAPK) cascade. J Biol Chem. 273:1998;32400-32407.
136. Cohen L.E., Hashimoto Y., Zanger K., Wondisford F., Radovick S. CREB-independent regulation by CBP is a novel mechanism of human growth hormone gene expression. J Clin Invest. 104:1999;1123-1130.
137. Liu Y.Z., Thomas N.S., Latchman D.S. CBP associates with the p42/p44 MAPK enzymes and is phosphorylated following NGF treatment. Neuroreport. 10:1999;1239-1243.
138. Sif S., Stukenberg P.T., Kirschner M.W., Kingston R.E. Mitotic inactivation of a human SWI/SNF chromatin remodeling complex. Genes Dev. 12:1998;2842-2851.
139. Masumi A., Wang I.M., Lefebvre B., Yang X.J., Nakatani Y., Ozato K. The histone acetylase PCAF is a phorbol-ester-inducible coactivator of the IRF family that confers enhanced interferon responsiveness. Mol Cell Biol. 19:1999;1810-1820.
140. Davie J.R., Samuel S.K., Spencer V.A., Holth L.T., Chadee D.N., Peltier C.P., Sun J.M., Chen H.Y., Wright J.A. Organization of chromatin in cancer cells Role of signalling pathways. Biochem Cell Biol. 77:1999;265-275.
141. Sassone-Corsi P., Mizzen C.A., Cheung P., Crosio C., Monaco L., Jacquot S., Hanauer A., Allis C.D. Requirement of Rsk-2 for epidermal growth factor-activated phosphorylation of histone H3. Science. 285:1999;886-891.
142. Thomson S., Mahadevan L.C., Clayton A.L. MAP kinase-mediated signalling to nucleosomes and immediate-early gene induction. Semin Cell Dev Biol. 10:1999;205-214.
143. Versaw W.K., Blank V., Andrews N.M., Bresnick E.H. Mitogen-activated protein kinases enhance long-range activation by the β-globin locus control region. Proc Natl Acad Sci USA. 95:1998;8756-8760.
144. Bottazzi M.E., Zhu X., Bohmer R.M., Assoian R.K. Regulation of p21(cip1) expression by growth factors and the extracellular matrix reveals a role for transient ERK activity in G1 phase. J Cell Biol. 146:1999;1255-1264.
145. Magnaghi-Jaulin L., Ait-Si-Ali S., Harel-Bellan A. Histone acetylation in signal transduction by growth regulatory signals. Semin Cell Dev Biol. 10:1999;197-203.
146. Pumiglia K.M., Decker S.J. Cell cycle arrest mediated by the MEK/mitogen-activated protein kinase pathway. Proc Natl Acad Sci USA. 94:1997;448-452.
147. Chau A.S., Shibuya E.K. Inactivation of p42 mitogen-activated protein kinase is required for exit from M-phase after cyclin destruction. J Biol Chem. 274:1999;32085-32090.
148. Roberts C.J., Nelson B., Marton M.J., Stoughton R., Meyer M.R., Bennett H.A., He Y.D., Dai H., Walker W.L., Hughes T.R., Tyers M., Boone C., Friend S.H. Signaling and circuitry of multiple MAPK pathways revealed by a matrix of global gene expression profiles. Science. 287:2000;873-880.
149. Bensaude O., Bonnet F., Casse C., Dubois M.F., Nguyen V.T., Palancade B. Regulated phosphorylation of the RNA polymerase II C-terminal domain (CTD). Biochem Cell Biol. 77:1999;249-255.
150. Bonnet F., Vigneron M., Bensaude O., Dubois M.F. Transcription-independent phosphorylation of the RNA polymerase II C-terminal domain (CTD) involves ERK kinases (MEK1/2). Nucleic Acids Res. 27:1999;4399-4404.
151. Whitmarsh A.J., Davis R.J. A central control for cell growth. Nature. 403:2000;255-256.
152. Plaisance S., Vanden Berghe W., Boone E., Fiers W., Haegeman G. Recombination signal sequence binding protein Jκ is constitutively bound to the NF-κB site of the interleukin-6 promoter and is a negative regulatory factor. Mol Cell Biol. 17:1997;3733-3743.
153. Kao H.Y., Ordentlich P., Koyano-Nakagawa N., Tang Z., Downes M., Kintner C.R., Evans R.M., Kadesch T. A histone deacetylase corepressor complex regulates the Notch signal transduction pathway. Genes Dev. 12:1998;2269-2277.
154. Hsieh J.J., Zhou S., Chen L., Young D.B., Hayward S.D. CIR, a corepressor linking the DNA binding factor CBF1 to the histone deacetylase complex. Proc Natl Acad Sci USA. 96:1999;23-28.
155. Dumont A., Hehner S.P., Schmitz M.L., Gustafsson J.A., Liden J., Okret S., Van der Saag P.T., Wissink S., van der Burg B., Herrlich P., Haegeman G., De Bosscher K., Fiers W. Cross-talk between steroids and NF-κB What language? Trends Biochem Sci. 23:1998;233-235.
156. Wissink S., van Heerde E.C., van der Burg B., van der Saag P.T. A dual mechanism mediates repression of NF-κB activity by glucocorticoids. Mol Endocrinol. 12:1998;355-363.
157. Brostjan C., Anrather J., Csizmadia V., Stroka D., Soares M., Bach F.H., Winkler H. Glucocorticoid-mediated repression of NF-κB activity in endothelial cells does not involve induction of IκB-α synthesis. J Biol Chem. 271:1996;19612-19616.
158. De Bosscher K., Schmitz M.L., Vanden Berghe W., Plaisance S., Fiers W., Haegeman G. Glucocorticoid-mediated repression of nuclear factor-κB-dependent transcription involves direct interference with transactivation. Proc Natl Acad Sci USA. 94:1997;13504-13509.
159. Heck S., Bender K., Kullmann M., Gottlicher M., Herrlich P., Cato A.C. IκB-α-independent downregulation of NF-κB activity by glucocorticoid receptor. EMBO J. 16:1997;4698-4707.
160. Vanden Berghe W., Francesconi E., De Bosscher K., Resche-Rigon M., Haegeman G. Dissociated glucocorticoids with anti-inflammatory potential repress interleukin-6 gene expression by a nuclear factor-κB-dependent mechanism. Mol Pharmacol. 56:1999;797-806.
161. Sheppard K.A., Phelps K.M., Williams A.J., Thanos D., Glass C.K., Rosenfeld M.G., Gerritsen M.E., Collins T. Nuclear integration of glucocorticoid receptor and nuclear factor-κB signaling by CREB-binding protein and steroid receptor coactivator-1. J Biol Chem. 273:1998;29291-29294.
162. Robyr D., Wolffe A.P., Wahli W. Nuclear hormone receptor coregulators in action Diversity for shared tasks. Mol Endocrinol. 14:2000;329-347.
163. Schmitz M.L., Stelzer G., Altmann H., Meisterernst M., Baeuerle P.A. Interaction of the COOH-terminal transactivation domain of p65 NF-κB with TATA-binding protein, transcription factor IIB, and coactivators. J Biol Chem. 270:1995;7219-7226.
164. Meyer T., Carlstedt-Duke J., Starr D.B. A weak TATA box is a prerequisite for glucocorticoid-dependent repression of the osteocalcin gene. J Biol Chem. 272:1997;30709-30714.
165. Yamit-Hezi A., Dikstein R. TAF(II)105 mediates activation of anti-apoptotic genes by NF-κB. EMBO J. 17:1998;5161-5169.
166. Zhou J., Zwicker J., Szymanski P., Levine M., Tjian R. TAFII mutations disrupt Dorsal activation in the Drosophila embryo. Proc Natl Acad Sci USA. 95:1998;13483-13488.
167. De Bosscher K., Vanden Berghe W., Vermeulen L., Plaisance S., Boone E., Haegeman G. Glucocorticoids repress NF-κB-driven genes by disturbing the interaction of p65 with the basal transcription machinery, irrespective of coactivator levels in the cell. Proc Natl Acad Sci USA. 97:2000;3919-3924.
168. De Bosscher K, Vanden Berghe W and Haegeman G, Mechanisms of anti-inflammatory action and of immunosuppression by glucocorticoids: Negative interference of activated glucocorticoid receptor with transcription factors. J Neuroimmunol 1: in press, 2000.
169. Lefstin J.A., Yamamoto K.R. Allosteric effects of DNA on transcriptional regulators. Nature. 392:1998;885-888.
170. Caelles C., Gonzalez-Sancho J.M., Munoz A. Nuclear hormone receptor antagonism with AP-1 by inhibition of the JNK pathway. Genes Dev. 11:1997;3351-3364.
171. Gonzalez M.V., Gonzalez-Sancho J.M., Caelles C., Munoz A., Jimenez B. Hormone-activated nuclear receptors inhibit the stimulation of the JNK and ERK signalling pathways in endothelial cells. FEBS Lett. 459:1999;272-276.
172. Cissel D.S., Beaven M.A. Disruption of raf-1/heat shock protein 90 complex and raf signaling by dexamethasone in mast cells. J Biol Chem. 275:2000;7066-7070.
173. Delerive P., De Bosscher K., Besnard S., Vanden Berghe W., Peters J.M., Gonzalez F.J., Fruchart J.C., Tedgui A., Haegeman G., Staels B. Peroxisome proliferator-activated receptor α negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-κB and AP-1. J Biol Chem. 274:1999;32048-32054.
174. Shikama N., Lyon J., La Thangue N.B. The p300/CBP family Integrating signals with transcription factors and chromatin. Trends Cell Biol. 7:1997;230-236.
175. Janknecht R., Hunter T. Nuclear fusion of signaling pathways. Science. 284:1999;443-444.
176. Carey M. The enhanceosome and transcriptional synergy. Cell. 92:1998;5-8.
177. Wu W.H., Hampsey M. Transcription Common cofactors and cooperative recruitment. Curr Biol. 9:1999;R606-R609.
178. Hottiger M.O., Felzien L.K., Nabel G.J. Modulation of cytokine-induced HIV gene expression by competitive binding of transcription factors to the coactivator p300. EMBO J. 17:1998;3124-3134.
179. Wadgaonkar R., Phelps K.M., Haque Z., Williams A.J., Silverman E.S., Collins T. CREB-binding protein is a nuclear integrator of nuclear factor-κB and p53 signaling. J Biol Chem. 274:1999;1879-1882.
180. Bhattacharya S., Michels C.L., Leung M.K., Arany Z.P., Kung A.L., Livingston D.M. Functional role of p35srj, a novel p300/CBP binding protein, during transactivation by HIF-1. Genes Dev. 13:1999;64-75.
181. O’Connor M.J., Zimmermann H., Nielsen S., Bernard H.U., Kouzarides T. Characterization of an E1A-CBP interaction defines a novel transcriptional adapter motif (TRAM) in CBP/p300. J Virol. 73:1999;3574-3581.
182. Agarwal S., Rao A. Modulation of chromatin structure regulates cytokine gene expression during T cell differentiation. Immunity. 9:1998;765-775.
183. Agarwal S., Rao A. Long-range transcriptional regulation of cytokine gene expression. Curr Opin Immunol. 10:1998;345-352.
184. Gribnau J., de Boer E., Trimborn T., Wijgerde M., Milot E., Grosveld F., Fraser P. Chromatin interaction mechanism of transcriptional control in vivo. EMBO J. 17:1998;6020-6027.
185. Weinmann A.S., Plevy S.E., Smale S.T. Rapid and selective remodeling of a positioned nucleosome during the induction of IL-12 p40 transcription. Immunity. 11:1999;665-675.
186. Waddick K.G., Uckun F.M. Innovative treatment programs against cancer II. Nuclear factor-κB (NF-κB) as a molecular target. Biochem Pharmacol. 57:1999;9-17.
187. DeLuca C., Kwon H., Lin R., Wainberg M., Hiscott J. NF-κB activation and HIV-1 induced apoptosis. Cytokine Growth Factor Rev. 10:1999;235-253.
188. Tai D.I., Tsai S.L., Chen Y.M., Chuang Y.L., Peng C.Y., Sheen I.S., Yeh C.T., Chang K.S., Huang S.N., Kuo G.C., Liaw Y.F. Activation of nuclear factor κB in hepatitis C virus infection Implications for pathogenesis and hepatocarcinogenesis. Hepatology. 31:2000;656-664.
189. Baeuerle P.A., Baichwal V.R. NF-κB as a frequent target for immunosuppressive and anti-inflammatory molecules. Adv Immunol. 65:1997;111-137.
190. Chen F., Castranova V., Shi X., Demers L.M. New insights into the role of nuclear factor-κB, a ubiquitous transcription factor in the initiation of diseases. Clin Chem. 45:1999;7-17.
191. Beyaert R. NF-κB as an emerging target in atopy. Emerg Ther Targets. 3:1999;1-16.
192. Neurath M.F., Becker C., Barbulescu K. Role of NF-κB in immune and inflammatory responses in the gut. Gut. 43:1998;856-860.
193. Jobin C., Sartor R.B. The IκB/NF-κB system A key determinant of mucosal inflammation and protection. Am J Physiol Cell Physiol. 278:2000;C451-C462.
194. Barnes P.J., Adcock I.M. Transcription factors and asthma. Eur Respir J. 12:1998;221-234.
195. Barnes P.J. Novel approaches and targets for treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 160:1999;S72-S79.
196. Jue D.M., Jeon K.I., Jeong J.Y. Nuclear factor κB (NF-κB) pathway as a therapeutic target in rheumatoid arthritis. J Korean Med Sci. 14:1999;231-238.
197. Christman J.W., Lancaster L.H., Blackwell T.S. Nuclear factor κB A pivotal role in the systemic inflammatory response syndrome and new target for therapy. Intensive Care Med. 24:1998;1131-1138.
198. Lyss G., Knorre A., Schmidt T.J., Pahl H.L., Merfort I. The anti-inflammatory sesquiterpene lactone helenalin inhibits the transcription factor NF-κB by directly targeting p65. J Biol Chem. 273:1998;33508-33516.
199. Bork P.M., Schmitz M.L., Kuhnt M., Escher C., Heinrich M. Sesquiterpene lactone containing Mexican Indian medicinal plants and pure sesquiterpene lactones as potent inhibitors of transcription factor NF-κB. FEBS Lett. 402:1997;85-90.
200. Yin M.J., Yamamoto Y., Gaynor R.B. The anti-inflammatory agents aspirin and salicylate inhibit the activity of IκB kinase-β Nature. 396:1998;77-80.
201. O’Neill E. A new target for aspirin. Nature. 396:1998;15-17.